Saudi consensus recommendations on the management of multiple sclerosis: MS management in children and adolescents Academic Article uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • Multiple sclerosis (MS) most commonly presents in young adults, although 3-5% of patients develop MS prior to the age of 18 years. The new and comprehensive consensus for the management of MS in Saudi Arabia includes recommendations for the management of MS and other CNS inflammatory demyelinating disorders in pediatric and adolescent patients. This article summarizes the key recommendations for the diagnosis and management of these disorders in young patients. Pediatric and adult populations with MS differ in their presentation and clinical course. Careful differential diagnosis is important to exclude alternative diagnoses such as acute disseminated encephalomyelitis (ADEM) or neuromyelitis optica spectrum disorders (NMOSD). The diagnosis of MS in a pediatric/adolescent patient is based on the 2017 McDonald diagnostic criteria, as in adults, once the possibility of ADEM or NMOSD has been ruled out. Few data are available from randomized trials to support the use of a specific disease-modifying therapy (DMT) in this population. Interferons and glatiramer acetate are preferred initial choices for DMTs based on observational evidence, with the requirement of a switch to a more effective DMT if breakthrough MS activity occurs.


  • Bunyan, Reem F
  • AlAbdulSalam, Abdulaziz M
  • Albarakati, Rayan G
  • Al Harbi, Awad A
  • Alissa, Dema A
  • Al-Jedai, Ahmed H
  • AlKhawajah, Nuha M
  • Al Malik, Yaser M
  • Almejally, Mousa A
  • Al-Mudaiheem, Hajer Y
  • AlNajashi, Hind A
  • AlShehri, Amani A
  • Althubaiti, Ibtisam A
  • AlYafeai, Rumaiza H
  • Babakkor, Mohammed A
  • Cupler, Edward J
  • Ka, Mamdouh H
  • Saeedi, Jameelah A
  • Shosha, Eslam
  • Al Jumah, Mohammed A

publication date

  • October 2022